Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia

Authors

Michael Tocco, Sunovion Pharmacueticals Inc.
John W Newcomer, Washington University School of Medicine in St. Louis
Yongcai Mao, Sunovion Pharmaceuticals Inc.
Andrei Pikalov, Sunovion Pharmaceuticals Inc.
Antony Loebel, Sunovion Pharmaceuticals Inc.

Journal

CNS spectrums

Publication Date

9-14-2020

Volume

26

Issue

6

First Page

614

Last Page

624

Document Type

Open Access Publication

DOI

10.1017/S1092852920001698

Rights and Permissions

Tocco, M., Newcomer, J., Mao, Y., Pikalov, A., & Loebel, A. (2021). Lurasidone and risk for metabolic syndrome: Results from short- and long-term clinical studies in patients with schizophrenia. CNS Spectrums, 26(6), 614-624. doi:10.1017/S1092852920001698 The Author(s), 2020. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. https://www.cambridge.org/core/

Recommended Citation

Tocco, Michael; Newcomer, John W; Mao, Yongcai; Pikalov, Andrei; and Loebel, Antony, "Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia." CNS spectrums. 26, 6. 614 - 624. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/11120